Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 31, 2021
Regulation

How omics will drive the next generation of surrogate endpoints

Next-gen tools offer more complete views of disease, drug response, but constraining their outputs is key
BioCentury | Aug 31, 2021
Regulation

Turning biomarkers into surrogates, starting with the familiar 

Mining decades of clinical practice, three fields are making surrogate endpoints out of common prognostic markers
BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

Emerging Company Profile: Cardior is betting on RNA therapies that aim to help dysfunctional hearts pump more efficiently.
BioCentury | Feb 28, 2020
Distillery Therapeutics

An antisense oligo inhibitor of miR-132 for heart failure

BioCentury | Feb 1, 2020
Preclinical News

Cardior eyes heart failure cure with miRNA inhibitor

BioCentury | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

How the diabetes and CV fields should organize to gain new biomarkers
BioCentury | Apr 27, 2018
Clinical News

Prothena discontinues AL amyloidosis candidate

Items per page:
1 - 10 of 74